TY - JOUR
T1 - Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores
T2 - A prospective randomized trial
AU - Bukulmez, Orhan
AU - Al, Atakan
AU - Gurdal, Hakan
AU - Yarali, Hakan
AU - Ulug, Berna
AU - Gurgan, Timur
PY - 2001
Y1 - 2001
N2 - Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.
AB - Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.
KW - Conjugated estrogens
KW - Hormone replacement therapy
KW - Medroxyprogesterone acetate
KW - Mood
KW - Platelet-tritiated imipramine binding
KW - Tibolone
UR - http://www.scopus.com/inward/record.url?scp=0035056978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035056978&partnerID=8YFLogxK
U2 - 10.1016/S0015-0282(01)01669-7
DO - 10.1016/S0015-0282(01)01669-7
M3 - Article
C2 - 11287028
AN - SCOPUS:0035056978
SN - 0015-0282
VL - 75
SP - 737
EP - 743
JO - Fertility and sterility
JF - Fertility and sterility
IS - 4
ER -